Phase 4 Heart Disease Trial, Recruiting NCT06451198 Sponsor: Shanghai Zhongshan Hospital Condition: Heart Disease
Back to Heart Disease

Phase 4 Heart Disease Trial, Recruiting

NCT06451198
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are over 65 years old
  • People who have been diagnosed with a type of heart condition called acute coronary syndrome (this includes unstable angina, or a heart attack with or without a specific pattern on a heart tracing test)
  • People who have been treated with at least one small mesh tube (called a drug-eluting stent) placed inside a blocked heart artery
  • People who are currently taking two blood-thinning medicines together: aspirin and ticagrelor
  • People who agree to attend and participate in the trial

Who may not be able to join:

  • People who have a planned non-emergency surgery scheduled within the next 12 months
  • People whose life expectancy is estimated at one year or less
  • People with a known allergy or bad reaction to aspirin, ticagrelor, or anti-inflammatory medicines (such as ibuprofen)
  • People who have previously had bleeding in the brain
  • People who have had a stroke within the past six months
  • People who are currently experiencing active bleeding
  • People with known significant abnormalities in their blood (confirm with trial site)
  • People with known low platelet levels or low red blood cell levels (anaemia) beyond a certain threshold (confirm with trial site for specific values)
  • People with active cancer
  • People who are currently taking blood-thinning tablets by mouth (oral anticoagulants, such as warfarin)
  • People who are already taking part in another clinical trial
  • People whom the trial doctor considers unsuitable for the study for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: 8615901823966

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
19 May 2025
Est. completion
31 December 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

net adverse clinical events (NACEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov